ADC Therapeutics (NYSE: ADCT) furnishes updated corporate presentation in 8-K filing

Rhea-AI Filing Summary

ADC Therapeutics SA furnished a current report to let investors know it has made an updated corporate presentation available. The presentation, dated September 30, 2025, is attached as Exhibit 99.1. The company notes that this material is being provided under Regulation FD and is not considered filed for liability purposes under the Exchange Act.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

false 0001771910 0001771910 2025-09-30 2025-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): September 30, 2025

ADC Therapeutics SA

(Exact Name of Registrant as Specified in Its Charter)

Switzerland (State or Other Jurisdiction of Incorporation) 001-39071 (Commission File Number) N/A (IRS Employer Identification Number)

Biopôle Route de la Corniche 3B 1066 Epalinges Switzerland (Address of Principal Executive Offices) (Zip Code) +41 21 653 02 00 (Registrant’s Telephone Number)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered
Common Shares, par value CHF 0.08 per share	ADCT	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 C.F.R. §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 C.F.R. §240.12b-2). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On September 30, 2025, ADC Therapeutics SA (the “Company”) made available an updated corporate presentation. A copy of the corporate presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

The information contained in these Items and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Corporate presentation
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ADC Therapeutics SA
Date: September 30, 2025
	By:	/s/ Peter J. Graham
	Name:	Peter J. Graham
	Title:	Chief Legal Officer

FAQ

What did ADC Therapeutics (ADCT) disclose in this 8-K filing?

ADC Therapeutics disclosed that it made an updated corporate presentation available. The presentation is furnished under Regulation FD and attached as Exhibit 99.1, giving investors additional background on the company without creating new Exchange Act filing liabilities.

What is Exhibit 99.1 in ADC Therapeutics’ latest 8-K for ADCT?

Exhibit 99.1 is an updated corporate presentation from ADC Therapeutics. It provides investors with company information and is furnished, not filed, meaning it is not subject to Section 18 liability unless later specifically incorporated into another securities filing.

Is ADC Therapeutics’ updated corporate presentation considered filed with the SEC?

No, the updated corporate presentation is expressly treated as furnished, not filed. ADC Therapeutics states it is not subject to Section 18 liabilities and is only incorporated into other securities filings if specifically referenced there by the company.

Which ADC Therapeutics officer signed the September 30, 2025 ADCT 8-K?

The 8-K was signed on behalf of ADC Therapeutics by Peter J. Graham. He is identified in the report as the company’s Chief Legal Officer, acting as the duly authorized representative for this current report filing.

What securities of ADC Therapeutics (ADCT) are listed on the NYSE?

ADC Therapeutics lists its common shares on the New York Stock Exchange. The table in the filing shows common shares with a par value of CHF 0.08 per share trading under the symbol ADCT on the NYSE.